PERITONEAL DIALYSATE FLUID, PERITONEAL DIALYSATE FLUID SET, COMPOSITION FOR USE IN PERITONEAL DIALYSIS, AND PERITONEAL DIALYSIS METHOD

• Main Author: TAKAHASHI HIROAKI
• Format: Patent
• Language: Chinese; English
• Published: 30.10.2020
• Subjects: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention provides a means which can appropriately control the balance between water and sodium in peritoneal dialysis therapies while avoiding adverse effects on the residual renal function and without causing hyponatremia. This peritoneal dialysate fluid contains 1.5 to 1.8 w/v% of glucose and 120 to 130 mEq/L of sodium, and is used alone one or two times a day. The peritoneal dialysate fluid is used in combination with another peritoneal dialysate fluid containing 1.35 to 2.5 w/v% of glucose and 132 to 135 mEq/L of sodium in peritoneal dialysis where the following steps are performed three to five times a day: injecting 1.5 to 2.0 L of a peritoneal dialysate fluid into the abdominal cavity of a subject; retaining the peritoneal dialysate fluid; and discharging the peritonealdialysate fluid. 本发明提供一种在腹膜透析治疗中不会引起低钠血症、能够在避免对残余肾功能造成不良影响的同时适当管理水与钠的平衡的手段。本发明的腹膜透析液含有1.5～1.8w/v％的葡萄糖及120～130mEq/L的钠，每天单独使用1～2次，在每天3～5次、1次将1.5～2.0L的量注入对象的腹腔内并贮存及排液的腹膜透析中，该腹膜透析液与含有1.35～2.5w/v％的葡萄糖及132～135mEq/L的钠的其他腹膜透析液组合使用。